Literature summary for 3.4.24.B11 extracted from

Sabatine, M.S.; Ploughman, L.; Simonsen, K.L.; Iakoubova, O.A.; Kirchgessner, T.G.; Ranade, K.; Tsuchihashi, Z.; Zerba, K.E.; Long, D.U.; Tong, C.H.; Packard, C.J.; Pfeffer, M.A.; Devlin, J.J.; Shepherd, J.; Campos, H.; Sacks, F.M.; Braunwald, E.
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy (2008), Arterioscler. Thromb. Vasc. Biol., 28, 562-567.

Search for more literature for 3.4.24.B11

Application

Application	Comment	Organism
medicine	in men not on pravastatin, those homozygous for the 227Pro allele of ADAMTS1 have a nearly 2-fold increased risk of coronary heart disease events compared with noncarriers. In this high-risk group, treatment with pravastatin is highly efficacious, reducing the odds of fatal coronary disease or nonfatal myocardial infarction by approximately 75%, as compared with 25% in noncarriers or heterozygotes	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q9UHI8	-	-

Synonyms

Synonyms	Comment	Organism
ADAMTS1 matrix metalloproteinase	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)